Dermatology

Tildrakizumab-asmn (Ilumya), an injectable interleukin-23 (IL-23) inhibitor, was approved by the FDA in March for adults who are candidates for systemic therapy or phototherapy.

Top news of the day from across the health care landscape.

Phase 3 trial results for dupilumab (Dupixent) demonstrate improvement in skin clearing, itch, and certain quality of life measurements for adolescents with atopic dermatitis.

In its latest report, the Institute for Clinical and Economic Review (ICER) evaluated the efficacy and value of newer targeted agents that treat moderate-to-severe plaque psoriasis compared with non-targeted therapies.

Patients whose psoriasis covers a large percentage of their body face a significantly higher risk of death than those who do not have the disease, according to results of a recent study.

The FDA has approved an updated label for Eli Lilly’s ixekizumab (Taltz) injection 80 mg/mL to include data in psoriasis involving the genital area.

Risankizumab shows promise as an important treatment option for people living with plaque psoriasis.

The FDA has approved ILUMYA (tildrakizumab-asmn, Sun Pharma) for treating adults with moderate-to-severe plaque psoriasis.

An estimation and comparison of the cost of home phototherapy versus biologics over a 3-year time horizon in patients with moderate-to-severe plaque psoriasis.

An immunomodulatory cytokine interacts with its receptors differently than other cytokines.

Inhibiting a specific protein reduces the clinical characteristics of atomic dermatitis.

The FDA has approved Tremfya (guselkumab, Janssen Biotech, Inc) for the treatment of adult patients with moderate to severe plaque psoriasis who are candidates for systemic therapy or phototherapy.

Investigational JAK1-selective inhibitor may reduce the symptoms of atopic dermatitis.

Only 38.3% of non-Hispanic minorities with psoriasis visited a dermatologist.

Up to 90% of patients with psoriasis develop plaque on their nails, palms of the hands, and soles of the feet.

Hay fever and asthma are dependent on allergens that stimulate the immunoglobulin E pathway, which is not the case with atopic dermatitis.

A newly-discovered eczema subtype may be linked to asthma and allergies.

Ixekizumab found to provide significant improvement in joint symptoms for patients not previously treated with a biologic disease-modifying antirheumatic drug.

Patients with moderate-to-severe nail psoriasis treated with secukinumab experienced significant improvement in the Nail Psoriasis Severity Index.

A look at last week's top stories in the world of pharmacy.

A look at last week's top stories in the world of pharmacy.

Patients with severe psoriasis were 64% more likely to develop diabetes than control patients.

Adhering to breastfeeding guidelines could cut the risk of eczema for offspring in half.

The type of inflammatory condition may increase the risk of liver disease, despite similar treatment.

The efficacy and safety of an adalimumab biosimilar matched the reference products in switching studies treating plaque psoriasis and rheumatoid arthritis.

Secukinumab (Cosentyx) treatment observed to improve the signs and symptoms of psoriatic arthritis.

New Drug Applications filed for halobetasol propionate and tazarotene lotion, a topical treatment for plaque psoriasis.

Treatment for psoriatic arthritis may impact symptoms and patient-reported outcomes.

Patients with active psoriatic arthritis experience significant work instability based on disease activity.